Total Payments
$509.71
2023 Payments
$123.17
Companies
8
Transactions
23
Medicare Patients
332
Medicare Billing
$35,322
Payment Breakdown by Category
Food & Beverage$425.32 (83.4%)
Education$84.39 (16.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $425.32 | 20 | 83.4% |
| Education | $84.39 | 3 | 16.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $123.17 | 1 | $0 (2023) |
| Allergan Inc. | $122.48 | 7 | $0 (2017) |
| Astellas Pharma US Inc | $92.97 | 3 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $90.42 | 6 | $0 (2020) |
| The Medicines Company | $38.07 | 3 | $0 (2017) |
| Otsuka America Pharmaceutical, Inc. | $18.54 | 1 | $0 (2021) |
| Gilead Sciences, Inc. | $13.68 | 1 | $0 (2022) |
| PFIZER INC. | $10.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $123.17 | 1 | ABBVIE INC. ($123.17) |
| 2022 | $13.68 | 1 | Gilead Sciences, Inc. ($13.68) |
| 2021 | $18.54 | 1 | Otsuka America Pharmaceutical, Inc. ($18.54) |
| 2020 | $11.72 | 1 | Merck Sharp & Dohme Corporation ($11.72) |
| 2017 | $342.60 | 19 | Allergan Inc. ($122.48) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/01/2023 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $123.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/26/2022 | Gilead Sciences, Inc. | Veklury (Drug) | Education | In-kind items and services | $13.68 | General |
| Category: COVID-19 | ||||||
| 04/22/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: NEPHROLOGY | ||||||
| 01/13/2020 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Education | In-kind items and services | $11.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/27/2017 | The Medicines Company | MINOCIN IV (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/10/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/04/2017 | Astellas Pharma US Inc | Cresemba (Drug), Mycamine | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Infectious Diseases | ||||||
| 05/04/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/13/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/12/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/06/2017 | Astellas Pharma US Inc | Mycamine (Drug), Ambisome | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Infectious Diseases | ||||||
| 03/24/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $20.14 | General |
| 03/16/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/16/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/28/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/25/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/15/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/14/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/25/2017 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: VACCINES | ||||||
| 01/18/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/12/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $58.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 56 | 72 | $20,289 | $5,705 |
| 2022 | 4 | 88 | 135 | $30,099 | $9,503 |
| 2021 | 4 | 76 | 115 | $25,549 | $8,443 |
| 2020 | 5 | 112 | 143 | $37,201 | $11,671 |
Total Patients
332
Total Services
465
Medicare Billing
$35,322
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 24 | $9,415 | $2,451 | 26.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 30 | $5,930 | $1,870 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 18 | $4,944 | $1,385 | 28.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 62 | $9,734 | $3,399 | 34.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 25 | $9,300 | $2,365 | 25.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 29 | $6,583 | $2,279 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 19 | $4,482 | $1,459 | 32.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 53 | $8,321 | $2,805 | 33.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 22 | $8,184 | $2,302 | 28.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 22 | $4,994 | $1,697 | 34.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 18 | $4,050 | $1,640 | 40.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 30 | 32 | $11,904 | $3,230 | 27.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 34 | 53 | $8,321 | $2,976 | 35.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $7,472 | $2,550 | 34.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 27 | $6,129 | $2,082 | 34.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 15 | $3,375 | $832.90 | 24.7% |
About Dr. Hanine El Haddad, M.D
Dr. Hanine El Haddad, M.D is a Internal Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2012. The National Provider Identifier (NPI) number assigned to this provider is 1801143268.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hanine El Haddad, M.D has received a total of $509.71 in payments from pharmaceutical and medical device companies, with $123.17 received in 2023. These payments were reported across 23 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($425.32).
As a Medicare-enrolled provider, El Haddad has provided services to 332 Medicare beneficiaries, totaling 465 services with total Medicare billing of $35,322. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease, Infectious Disease
- Location Dallas, TX
- Active Since 08/04/2012
- Last Updated 10/29/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801143268
Products in Payments
- TEFLARO (Drug) $174.57
- AVYCAZ (Drug) $71.08
- ZERBAXA (Drug) $44.77
- ORBACTIV (Drug) $25.67
- JYNARQUE (Drug) $18.54
- Cresemba (Drug) $18.12
- Mycamine (Drug) $15.86
- CUBICIN RF (Drug) $13.79
- Veklury (Drug) $13.68
- MINOCIN IV (Drug) $12.40
- PREVYMIS (Drug) $11.72
- PREVNAR - 13 (Biological) $10.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dallas
Andrew Whiteley
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Biff Palmer, Md, MD
Internal Medicine — Payments: $980,569
Internal Medicine $980,569
Dr. Robert Gottlieb, M.d. Ph.d, M.D. PH.D
Internal Medicine — Payments: $832,284
Internal Medicine $832,284
Dr. Ronan Kelly, Md, MD
Internal Medicine — Payments: $813,092
Internal Medicine $813,092
Dr. Gates Colbert, M.d, M.D
Internal Medicine — Payments: $801,349
Internal Medicine $801,349
Dr. Zoran Kurepa, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $743,379
Internal Medicine $743,379